drugset / Trial / NCT05571319
A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.
Phase 2
Completed
30 enrolled
University of Stellenbosch
Fogarty International Center of the National Institute of Health · collabUniversity of Rochester · collab
NaSingle-groupOpen-labelTreatment
Summary
Metabolic syndrome is a constellation of risk factors for cardiovascular disease and type 2 diabetes mellitus which frequently occur together. Data is emerging suggesting metabolic syndrome causes brain disease by contributing to blood vessel damage and inflammation. People living with HIV (PLWH) are at high risk and the investigators will perform a pilot study of the well-known type 2 diabetes drug metformin to treat this blood vessel damage and inflammation in PLWH.
Timeline
- Start
- 2022-08-11
- Primary completion
- 2025-03-24
- Completion
- 2025-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 1000 mg | Oral |
| Subject | Metformin | Small molecule | 2000 mg | Oral |